SuperworthOcular Therapeutix EPS OCUL
Diluted earnings per share by quarter and over the last twelve months, from 2013.
- Last 12 months, to Jun 30, 2026
- −$1.42
- Latest quarter, Q2 FY26
- −$0.35
- Fiscal year 2025
- −$1.44
Ocular Therapeutix's earnings per share was −$1.42 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was −$0.35.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.44 | n/a |
| FY2024 | −$1.26 | n/a |
| FY2023 | −$1.25 | n/a |
| FY2022 | −$0.98 | n/a |
| FY2021 | −$0.77 | n/a |
| FY2020 | −$2.47 | n/a |
| FY2019 | −$2.00 | n/a |
| FY2018 | −$1.57 | n/a |
| FY2017 | −$2.20 | n/a |
| FY2016 | −$1.81 | n/a |
| FY2015 | −$1.70 | n/a |
| FY2014 | −$5.40 | n/a |
| FY2013 | −$5.11 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.35 | n/a | −$1.42 | |
| Q1 FY26 | −$0.40 | n/a | −$1.46 | |
| Q4 FY25 | −$0.29 | n/a | −$1.44 | |
| Q3 FY25 | −$0.38 | n/a | −$1.44 | |
| Q2 FY25 | −$0.39 | n/a | −$1.28 | |
| Q1 FY25 | −$0.38 | n/a | −$1.15 | |
| Q4 FY24 | −$0.29 | n/a | −$1.26 | |
| Q3 FY24 | −$0.22 | n/a | −$1.32 | |
| Q2 FY24 | −$0.26 | n/a | −$1.35 | |
| Q1 FY24 | −$0.49 | n/a | −$1.35 | |
| Q4 FY23 | −$0.35 | n/a | −$1.25 | |
| Q3 FY23 | −$0.25 | n/a | −$1.10 |
Against its peers
Companies in Drug Manufacturers - General nearest Ocular Therapeutix's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| OCULOcular Therapeutix | −$1.42 | |
| PCRXPacira BioSciences | $0.35 | |
| ANABAnaptysbio | $4.57 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANIPANI Pharmaceuticals | $4.70 | |
| OMEROmeros | $1.52 | |
| AMPHAmphastar Pharmaceuticals | $1.70 | −36% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| ABUSArbutus Biopharma | $0.78 | |
| COLLCollegium Pharmaceutical | $1.24 | +19% a year |
| Peer median | $2.07 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Ocular Therapeutix
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.